Back to Search
Start Over
Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer.
- Source :
-
Frontiers in genetics [Front Genet] 2022 Jan 03; Vol. 12, pp. 723477. Date of Electronic Publication: 2022 Jan 03 (Print Publication: 2021). - Publication Year :
- 2022
-
Abstract
- Background: Breast cancer is one of the deadly tumors in women, and its incidence continues to increase. This study aimed to identify novel therapeutic molecules using RNA sequencing (RNA-seq) data of breast cancer from our hospital. Methods: 30 pairs of human breast cancer tissue and matched normal tissue were collected and RNA sequenced in our hospital. Differentially expressed genes (DEGs) were calculated with raw data by the R package "edgeR", and functionally annotated using R package "clusterProfiler". Tumor-infiltrating immune cells (TIICs) were estimated using a website tool TIMER 2.0. Effects of key genes on therapeutic efficacy were analyzed using RNA-seq data and drug sensitivity data from two databases: the Cancer Cell Line Encyclopedia (CCLE) and the Cancer Therapeutics Response Portal (CTRP). Results: There were 2,953 DEGs between cancerous and matched normal tissue, as well as 975 DEGs between primary breast cancer and metastatic breast cancer. These genes were primarily enriched in PI3K-Akt signaling pathway, calcium signaling pathway, cAMP signaling pathway, and cell cycle. Notably, CD8 <superscript>+</superscript> T cell, M0 macrophage, M1 macrophage, regulatory T cell and follicular helper T cell were significantly elevated in cancerous tissue as compared with matched normal tissue. Eventually, we found five genes ( GALNTL5, MLIP, HMCN2, LRRN4CL, and DUOX2 ) were markedly corelated with CD8 <superscript>+</superscript> T cell infiltration and cytotoxicity, and associated with therapeutic response. Conclusion: We found five key genes associated with tumor progression, CD8 <superscript>+</superscript> T cell and therapeutic efficacy. The findings would provide potential molecular targets for the treatment of breast cancer.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Zhang, Tong, Wei, Chen, Liang, Tang, Wu, Wen, Yang, Liang and Shen.)
Details
- Language :
- English
- ISSN :
- 1664-8021
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in genetics
- Publication Type :
- Academic Journal
- Accession number :
- 35046993
- Full Text :
- https://doi.org/10.3389/fgene.2021.723477